RecruitingNCT07215923
ATI-1013 antibody for nicotine in adult smokers
About this title
Read the official source — NCT07215923Placebo researchAges 23–59United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 23 years to 59 years.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: October 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 15
- Sponsor
- Antidote Therapeutics, Inc
- Sponsor type
- Biotech company
- Study type
- Biological
- Intervention type
- BIOLOGICAL, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 23 Years to 59 Years
- Official registry ID
- NCT07215923
- Official title
Show the full official title
A First in Human, Double-Blind, Placebo-Controlled, Randomized Evaluation of Single Ascending Doses of ATI-1013, a Human Monoclonal Antibody to Nicotine in Healthy Smokers
Recruitment & locations
RecruitingOverland Park
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Antidote Therapeutics, Inc.
Who can participate?
Listed age limits: 23 years to 59 years.
Is this study still recruiting?
The registry lists this study as recruiting.
